Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
First support $8.35. Second support $8.03
Latest real-time trades:
https://www.nasdaq.com/market-activity/stocks/avxl/latest-real-time-trades
I expect to close out the week in the 7's. It could be the last buying opportunity for believers, IMO.
Get used to it! You won’t be disappointed…Guarenteed.
Why does the announcement text say “ completion of dosing” instead of complete of clinical trial? Maybe it’s my lack of trust in Missling. Maybe no big deal but seems confusing. Idk.
Our CEO on cover Fortune Magazine:
https://finance.yahoo.com/news/fortune-500-record-number-female-100000590.html
Checkered track record would certainly describe a CEO that is focused on bringing a product to market. Right on track would certainly describe a CEO that is getting all the ducks lined up and then not moving forward but stalling, waiting for a take-over bid. We are a small company with a massive portfolio. Small companies like us lack the wherewithal to bring a product to market unless they farm out the manufacturing, packaging and distribution, accepting the risk to quality control. Big Pharma has massive cash reserves but also have some of their big moneymakers coming off patent. Timing is everything. If Missling’s plan is the above, his timing seems to be coming online.
Quarterly Increase/Decrease AVXL holdings:
https://www.holdingschannel.com/holdings-changes/avxl/
“Expose the Criminals”. It seems to be systemic:
https://www.nbcnews.com/health/health-news/fda-broke-protocols-approving-biogen-alzheimers-drug-congressional-rep-rcna63662
The market has many different players with similar financial interests. I know of a company, when they brought their first drug to market, competing with 2 other already commercialized drugs for the same indication, actually got several bomb threats that caused evacuation of it's manufacturing plant. Maybe being embraced by the market is more the exception than the rule. On a positive note, though, the new drug became the most prescribed best seller of the 3. With our multiple indications, it would be nice to have a similar outcome.
Yadda, Yadda, Yadda!
I thought the FDA made some changes that were designed to bring drugs with an urgent need to market sooner. Maybe I'm one of those that doesn't get why a drug with minimal side effects and proven efficacy for various diseases doesn't seem to fit with those FDA changes. Glad Missling won't be the one sitting by the phone if I am in need of a 911 call. Best of luck to all.
Lincoln Park Capital Fund's past performance in the majority of companies that use this vulture fund show a sp decline of 38%. There are two ways to view this, though, as good or bad. Personally, I see this as an upcoming buying opportunity. Our ceo, Drysdale, seems a cut above the rest, IMO.
All of that sounds great. Still have my fingers and toes crossed. Is there a doctor in the house?
Maybe you are right. But I have been here 8 years so patience is not the issue. Could be, as you say, it takes a long time. Or it could be you getting caught up in the insanity yourself. Happy investing. Or maybe happy, happy investing is more appropriate. There is a place for happy, happy people. Maybe this is it,
Insane? The definition of the insanity of continuing with my investment here is me believing we are about to take off when each of our trials produce great results and nothing happens. Then believing Missling wants to get things just right. Thinking this time after time and expecting a different result sounds like insanity to me. I am at some stage of becoming a non-believer. WTF
What is beyond weird is biogen's past halting of aducanomab's (sp?) trial, then changing endpoints to reducing amyloid plaque and the FDA approval being based on that alone without consideration of the drug's efficacy.
Is this all a numbers game, calculating how much it costs the govt per year per persons over age 65 to survive vs allowing folks with AD to die by approving drugs that either don’t work or hasten death. I’m pretty sure AD will be on the list for euthanasia when that comes fully online. Add to that, the number of CNS diseases with no real cures on the market. What is the math that says a treatment that works to prolong the lives of populations no longer able to contribute financially to society is more cost effective than allowing people to die. Just trying to figure out why 1 + 1 doesn’t seem to equal 2 here. Why are biogen’s drugs being approved in lock step fashion. Maybe I think too much.
We can change the delivery method and receive a new patent.
Will this give our share price a boost?
https://finance.yahoo.com/news/virginia-community-health-centers-aetna-140000796.html
Cipcipcipcipcip
Which way are we going?
Don’t Think. You most certainly are setting yourself up for disappointment, in my opinion.
We have a very impressive CEO:
https://milkeninstitute.org/events/a0c1u00000cf19buar/speakers/doug-drysdale
Yesterday’s Panel discussion at Milken showed how far ahead we are in the quest to revolutionize the mental health care system.
Or if there were a drug that restored homeostasis....oh....I think we were told that our drug does that. Hate to say it but it’s begining to seem Missling is indeed selling snake oil to us investors. Sorry.
Too bad we couldn’t help this guy with Parkinson’s Disease or the folks with Alzheimer’s Disease or the girls with Rett Syndrome or the kids with Autism Spectrum Disorder. We don’t have time for that stuff...too busy doing never-ending clinical trials with no results:
https://www.msn.com/en-us/entertainment/news/michael-j-fox-reveals-heartbreaking-end-of-life/ar-AA1aExCe?li=BBnbfcL
It's called setting up for a takeover IMO.
Sad. Thank you for posting. Let's hope we can help settle the score for the kids and their families suffering from this horrible disease.
Patience is a Virtue, a very rewarding virtue for CYBN Longs, IMO.
Looks like a Hail Mary Pass to me.
Seems to me, A2-73 is being used as a substrate to identify the percent of binding to sigma 1 receptors or to quantify sigma 1 receptors.
Maybe he is getting tired of all of the smoke and mirrors too; new former FDA hires, new patents, data coming, etc. Anything shy of data is just that, smoke and mirrors, IMO.
It seems to me Dr Missling is lining all his trial data ducks up for a takeover. That’s what small bios do. Anyone looking for an accelerated approval for any of our indications will continue to be sadly disappointed, IMO. Sitting on the edge of my seat expecting takeoff, defies logic for me now. Missling doesn’t act like someone gearing up for commercialization. He will do very well with a takeover. I hope shareholders do as well.
How do we get approval if we don't bring our results to the FDA? We are not a one trick pony company. All of our trials had positive results. Why don't we make our case before the FDA for anything? That would open up the off label market. Something aien't right here.
Dr Missling did tell us many years ago that patients may need to be taking A2-73 for an extended period of time to receive maximum benefit, so this result may be proving him right. I wouldn’t want to be in a Fox hole with DM though, my weapon works, very efficacious, saves a lot of lives. Arrrhhh, how Do you pull the trigger?
As a shareholder, you have no right, absolutely no right, to any information on anything the company is doing or not doing. Dr Missling is the Leader. He is the ceo. Even if he is a fork up, he is still king of the mountain. I learned what my rights as a shareholder are, on this mb. Just thought I would share this wisdom.
I thought shareholders were part owners of the company. Why does begging for crumbs of information occupy so much space here? Missling seems to rule like a dictator. I’m usually not radical in my thinking but a shareholder uprising would suit me fine.
Great questions. I have been here from the beginning. Our lack of seeking approval for Alz, Rett, PD, Sleep…Something, is mind boggling on some days. Other days are more hopeful. With all of our successful trials, seeking approval for any neurological disease seems remotely possible. That’s when I’m believing Dr Missling knows what he is doing. Other days, forget about it.
Curious to know what it will take for Missling to “Come out swinging.” Phase III trial for Adult Rett Syndrome met Primary and Secondary endpoints over a year ago. What will it take to get the adrenaline pumping in this guy?
https://www.anavex.com/post/anavex-2-73-blarcamesine-avatar-phase-3-trial-met-primary-and-secondary-efficacy-endpoints?fbclid=IwAR1dEv4FH5FRCcM-iaSwPYCiFi5T2vCd1VgOGNkJ674IEOh1RrUBOZz0aGg
It is my belief in the Science that keeps my shares under lock and key. The cabal may try to generate fear.
Warren Buffett once said that it is wise for investors to be “fearful when others are greedy, and greedy when others are fearful.”
If my expendable finances allow and the cabal continues to succeed in bringing our share price down, I will be reloading.
There is a difference, a big difference between a clinical trial and Right To Try.
https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/right-try